[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100537298":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":33,"locations":39,"responsibleParty":57,"collaborators":25,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":25,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":25,"enrollmentInfo":70,"targetDuration":25,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":41,"whyStopped":25,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Beijing Anzhen Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"nafamostat mesilate group","EXPERIMENTAL","The initial dosing of the nafamostat mesilate group is 0.5mg\u002Fkg\u002Fh. We maintain ACT at 180\\~220s by adjusting the dosage of nafamostat mesilate.",[13],"Drug: nafamostat mesilate",{"label":15,"type":6,"description":16,"interventionNames":17},"unfractionated heparin group","The initial dosing of the unfractionated heparin group is 8\\~12U\u002Fkg\u002Fh. We maintain ACT at 180\\~220s by adjusting the dosage of unfractionated heparin .",[18],"Drug: unfractionated heparin group",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","nafamostat mesilate","Use nafamostat mesilate as an anticoagulant",[9],null,{"type":21,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Use unfractionated heparin as an anticoagulant",[15],[30],{"name":31,"affiliation":5,"role":32},"Zhongtao Du, MD","STUDY_CHAIR",[34],{"name":35,"role":36,"phone":37,"phoneExt":25,"email":38},"Xiaotong Hou, MD","CONTACT","010-64456631","xt.hou@ccmu.edu.cn",[40],{"facility":5,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Beijing","Beijing Municipality","100029","China","CN",{"type":48,"coordinates":49},"Point",[50,51],116.39723,39.9075,{"lat":51,"lon":50},[54],{"name":31,"role":36,"phone":55,"phoneExt":25,"email":56},"86-18610846901","zhongtaodu@126.com",{"type":58,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"SPONSOR_INVESTIGATOR","Xiaotong Hou","Clinical professor","100537298","use-of-nafamostat-mesilate-for-anticoagulation-in-patients-with-ecmo-100537298",false,"NCT06276010","Use of Nafamostat Mesilate for Anticoagulation in Patients With ECMO","Use of Nafamostat Mesilate for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation After Cardiac Surgery: Efficacy and Safety","Inclusion Criteria:\n\n1. Age ≥ 18 years old\n2. VA-ECMO or VV-ECMO was accepted after cardiac surgery.\n3. The ECMO treatment team believes that systemic anticoagulation is needed\n4. Sign the informed consent form\n\nExclusion Criteria:\n\n1. The researchers believe that there are other causes of active bleeding that are not suitable to participate in this study.\n2. Long-term use of anticoagulants before establishment of ECMO\n3. Antiplatelet drugs were used before the establishment of ECMO\n4. Severe liver insufficiency\n5. Connective tissue disease\n6. There is a history of allergy to heparin or nemolastat mesylate.\n7. Pregnant\n8. Previous diagnosis of heparin-induced thrombocytopenia\n9. Expect to die within 48 hours\n10. ECPR","ALL","18 Years",{"count":71,"type":72},80,"ESTIMATED","INTERVENTIONAL",[75],"NA","The purpose of this study is to evaluate the effectiveness and safety of nafamostat mesilate compared with unfractionated heparin for anticoagulation in patients with ECMO after cardiac surgery.",[78],"Extracorporeal Membrane Oxygenation Complication",[80,22],"anticoagulation","2025-09-22",{"date":83,"type":84},"2025-09-25","ACTUAL",{"date":86,"type":84},"2024-07-01",{"date":88,"type":72},"2026-12-31",{"name":59,"class":6},1]